Baxter Launches Fresh Initiative - Analyst Blog
14 4월 2011 - 8:45PM
Zacks
To mark World Hemophilia Day,
Baxter International (BAX) recently reiterated its
determination to maintain the standard of care and ensure adequate
access to treatment for victims of hemophilia and other bleeding
disorders. The company is extending its hand to the World
Federation of Hemophilia (“WFH”) to start Advocacy in Action, a
creative, multi-year project to assist nations play an advocacy
role for victims of bleeding disorders.
Baxter is funding this initiative
with a grant. Furthermore, Advocacy in Action’s role is intertwined
with the WFH theme for World Hemophilia Day, which is “Be Inspired,
Get Involved in Treatment for All”. Since its inception, in honor
of Frank Schnabel in 1989, World Hemophilia Day (observed on April
17) has played a key role in heightening awareness of hemophilia
and various bleeding problems.
The overall longevity of hemophilia
victims, in certain areas of the developed world, has crossed 60
years. Despite progress, wide disparities remain as 3 out of 4
victims do not receive proper medical care.
According to WFH, its purpose is to
make sure that all victims are diagnosed and receive treatment for
their condition. For its part, Advocacy in Action is geared to
accomplish this mission, which will lead to favorable results
across the globe.
Advocacy in Action is empowered to
bolster WFH’s national member organizations’ (“NMOs”) capability to
lobby their governments on behalf of those suffering from bleeding
disorders. The effort includes specially crafted advocacy support,
such as workshops, coaching programs and staffing to help implement
public policy.
Besides the new advocacy
initiative, Baxter continues to support WFH’s Global Alliance for
Progress (“GAP”) program as its founder cum leading sponsor. Since
its inception in 2003, over 22,000 victims have been diagnosed with
bleeding problems in 16 nations and over 13,000 health care experts
and regulators trained on the subject. Baxter has also reached out
to hemophilia patients living in underserved nations.
Baxter remains at the forefront of
R&D efforts to treat hemophilia A and B and von Willebrand
disease (a bleeding disorder afflicting both genders). Many
preclinical, clinical and post-marketing trials are under progress
to evaluate approaches for managing hemophilia.
Overall, the news regarding Baxter
remains mixed, at the Street. On the positive side, Baxter’s focus
on life-sustaining products, which are not commoditized, partly
insulates it from an economic downturn. The company is able to
generate recurring revenues, and consistent cash flow, due to its
focus on chronic diseases.
On the flip side, despite recent
improvement in Plasma Proteins and Antibody Therapy sub-segments,
we are concerned about stagnation in sales, a somewhat difficult
outlook for hospital spending and tightening of reimbursement.
The lingering bearishness
surrounding the stock can be lifted by consistent execution. Baxter
is a good bet for value investors willing to wait as fundamentals
improve. Among others, it competes with Becton, Dickinson
and Company (BDX) and Talecris Biotherapeutics
Holdings Corp. (TLCR) in certain niches. We currently have
a long-term Neutral rating on Baxter.
BAXTER INTL (BAX): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis Report
TALECRIS BIOTHR (TLCR): Free Stock Analysis Report
Zacks Investment Research
Talecris Biotherapeutics Holdings Corp. (MM) (NASDAQ:TLCR)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Talecris Biotherapeutics Holdings Corp. (MM) (NASDAQ:TLCR)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024